StemCell Therapy

Growing up in Livermore, California, Janelle Ayres kept all kinds of petsrabbits, birds, fish, turtles, and her two favorites, Smokey the Siberian husky and Roman the German shepherd. She dreamed of becoming a veterinarian, but learning about genetics in high school led her to study molecular and cell biology at the University of California (UC), Berkeley. She then had to choose among vet school, med school, and a PhD program. Attending a talk by Stanley Falkow, whom she calls the godfather of microbial pathogenesis, helped her decide to pursue microbiology. I loved the idea of host-microbe interactions, Ayres tells The Scientist, and that pathogens could be having such dramatic effects on the hosts biology.

After graduating in 2002, Ayres moved to Stanford to work with microbiologist David Schneider. He encouraged her to follow her own ideas, and after many hours spent PubMed wandering, she kept circling back to the same question: What does it mean to survive an infection? The dogma then was that surviving an infection required killing a pathogen, and while thats true in many cases, Ayres says, it didnt account for all infections.

Wheat, for example, can tolerate certain pathogens without treatment, leaving Ayres to wonder: if plants could endure infections, did animals also have this disease tolerance? To investigate, she injected fruit flies with Listeria. All of the flies, whether they died or not, had similar levels of bacteria, indicating that pathogen load or an inability to eradicate the infection wasnt what killed the insects. Ayres next analyzed the genetics of the flies and found tweaks in genes unrelated to the immune system that promoted tolerance of the infection. Animals, like plants, do tolerate disease, she showed.

Working on that project, Ayres was really engaged and thoughtful in a way that I now understand isnt very typical of graduate students, Schneider says. She finished her PhD in 2009 and returned to UC Berkeley for a postdoc in the lab of microbiologist and immunologist Russell Vance. Four years later, she opened her own lab at the Salk Institute for Biological Studies in La Jolla, California.

There, Ayres set out to investigate whether disease tolerance existed in mammals. She worked with mice, which tend to lose muscle mass after infection with Salmonella or Burkholderia thailandensis. And, just as in her earlier fruit fly experiment, she found that some mice experienced muscle wasting while others of the same strain didnt, even when the animals had similar pathogen levels. It turned out that a particular strain of E. coli in the microbiomes of surviving mice had helped them tolerate infection. Giving that E. coli strain to infected mice as a probiotic protected them against muscle wasting (Science, 350:55863, 2015).

Janelles work is remarkably creative in identifying mechanisms of tolerance and really digging deep and trying to understand how the mammalian host . . . can actually withstand typical bacterial infections, says Dan Littman, an immunologist at New York University who has tracked Ayress work. She has the ability to really think around problems without being held back by the conventional wisdom in the field.

In a 2017 Cellpaper, Ayres and her colleagues showed that when Salmonella typhimurium infects a mouse, the bacterium uses an effector protein called SlrP to manipulate the animals gut-brain axis. The mouse continues eating as a result, whereas with other infections the animal would lose its appetite. This manipulation of the animals behavior promotes host health and survival, along with pathogen transmission, Ayres says.

In a more recent experiment, she and her team analyzed gene activation in genetically identical mice infected with Citrobacter. Mice that survived had increased expression of genes regulated by iron. When her team fed iron-enriched chow to a new group of infected mice, 100 percent of the animals survived, despite the pathogens persistent presence in their organs.

Every experiment seems to surprise us, Ayres says, and were committed to pushing this field forward. The goal is translating the work into humans. When a patient is infected with a particular pathogen, she explains, I want to be able to define how I can intervene and shift them back onto a trajectory to a healthy state.

See the article here:
Janelle Ayres Explores the Ways in Which Animals Tolerate Disease - The Scientist

NEW YORK Employing tumor-normal sequencing, researchers have demonstrated that a significant number of advanced cancer patients learned germline findings that informed the treatment they received.

In one study, involving 12,000 patients treated at Memorial Sloan Kettering Cancer Center, researchers identified nearly 600 patients with recurrent or metastatic cancer who had actionable germline mutations, and 44 percent of them received targeted drugs either as part of the standard of care or as part of a research protocol.

Presenting the findings at the American Society of Clinical Oncology's virtual annual meeting, MSK's Zsofia Stadler said her group's study represents the most comprehensive assessment of the clinical utility of germline variants for guiding targeted therapy decisions in advanced cancer patients. This study, she said, demonstrates the "the importance of germline analysis for cancer treatment."

In another study, presented at the same meeting, researchers from the University of Michigan investigated the prevalence of actionable germline mutations in a cohort of around 1,000 patients, and found that 49 patients, or close to 5 percent, had therapeutically targetable germline mutations.

The findings from these two studies are timely given that cancer patients are increasingly having their tumors sequenced in the hopes of identifying precision therapy options. Studies have shown that after tumor profiling, approximately 10 percent of patients received results based on which they can receive precision drugs. Patients' tumors are often profiled using next-generation sequencing (NGS) panels that gauge hundreds of genes and also pick up clinically significant germline mutations, but often these findings are censored and not reported back to or discussed with the patient. This is likely because there is a perception that germline genetic mutations, which have been historically important for inherited cancer risk assessment, don't really impact the immediate care of patients.

"We know the identification of germline alterations has important implications for our cancer patients, including implementation of appropriate cancer surveillance measures, potential risk-reducing measures, and of course predictive genetic testing for at-risk relatives," said Stadler. "However, less is known about the clinical impact of germline findings on targeted cancer treatment."

At MSK, cancer patients can have their tumors profiled with the MSK-IMPACT NGS panel which gauges more than 400 genes. The goal of this testing, Stadler said, is to identify genetic mutations in the tumor that can be targeted with treatments. To do this, the cancer center sequences a patient's tumor tissue and normal blood sample, compares the detected mutations, and subtracts out the germline variants that occur in every cell in the body, not just the tumor. At the end of this process, only the somatic mutations found in the tumor are reported.

Starting in 2015, patients at MSK who received testing with MSK-IMPACT could provide consent under an institutional review board-approved protocol to receive separate germline testing for 88 genes associated with increased cancer risk. Between 2015 and 2019, nearly 12,000 patients agreed to this additional testing to learn if they harbored likely pathogenic or pathogenic mutations in any of these genes. If patients had pathogenic findings, this was noted in their medical record, which investigators then reviewed to assess whether the mutations could inform treatment.

Around half of these 12,000 tested patients had breast, prostate, pancreatic, or colorectal cancers, while the rest of the patients had a variety of rarer tumor types. Approximately 2,000 patients, or 17 percent, had likely pathogenic or pathogenic mutations, 682 of whom had mutations in high- or moderate-penetrance genes.

In terms of therapeutic actionability, Stadler and colleagues identified targetable mutations in 849 patients, or 7 percent. Since PARP inhibitors now can be given to patients with BRCA1 or BRCA2 mutations with certain types of cancers, mutations in these genes comprised more than half of the actionable findings. Nearly 20 percent of mutations were in Lynch syndrome genes, which can guide immunotherapy use.

MSK classifies the actionability of somatic variants detected by MSK-IMPACT using a three-tier system that emerged in the process of garnering FDA authorization for the panel. In authorizing that test, the FDA released a three-tier framework to help labs determine what information they could accurately communicate in test reports based on the evidence underlying detected biomarkers. The same system can also help oncologists prioritize which findings are most informative for their patient's care from the long list of genetic mutations often identified by these tests.

In the FDA's framework, tier 1 biomarkers are those that the agency has given companion diagnostic status based on evidence showing that they can determine which patients will or will not respond to a drug. Tier 2 biomarkers are "cancer mutations with evidence of clinical significance" that doctors can use in the care of cancer patients in line with guidelines and other information. Tier 3 biomarkers are "cancer mutations with potential clinical significance," which can help direct patients to clinical trials.

Since germline variations don't have a widely accepted system of classification for therapeutic actionability, Stadler and colleagues adapted this three-tier system for somatic variants to weigh the evidence on the 88 cancer risk genes. While 849 patients, or 7 percent, had targetable germline mutations in tier 1 and 2 genes, using all three tiers, around 1,000 patients, or nearly 9 percent, had germline mutations with therapeutic significance.

The researchers used the more stringent criteria germline mutations in tier 1 and 2 genes to try to guide treatment decisions for nearly 600 patients with recurrent or metastatic cancer. Ultimately, 44 percent received targeted drugs either as part of the standard of care or as part of a research protocol. Patients who received treatment had germline mutations in a variety of genes, though alterations in BRCA1 and BRCA2 drove a lot of the therapeutic decisions in the study.

As such, researchers explored this subset of patients in more detail. Of the 175 patients with BRCA1/2 germline mutations, 57 percent were classified as tier 1 mutations because patients had breast or ovarian cancer and were able to receive PARP inhibitors that had been FDA approved for their molecularly defined indication. More than 40 percent including 21 percent of pancreatic cancer patients and 11 percent of prostate cancer patients received PARP inhibitors under a research protocol. Since this study, however, the FDA has approved PARP inhibitors for BRCA-mutated pancreatic and prostate cancer.

"With the emergence of novel targeted treatments with new FDA indications, the therapeutic actionability of germline variants is likely to increase over time," Stadler said.

Germline testing for all advanced cancer patients?

The study led by Erin Cobain from the University of Michigan similarly demonstrated the clinical utility of germline findings from tumor testing, though on a smaller scale. The researchers conducted targeted exome sequencing for 1,700 genes and transcriptome sequencing on tumor and normal samples from approximately 1,000 patients with advanced solid tumors. Pathogenic germline variants were identified in 160 patients, or 16 percent. Of the deleterious cancer risk mutations identified during this process, 92 percent were not known before patients were tested as part of this protocol, "which indicates that current clinical criteria may not identify all patients at risk for cancer predisposition," Cobain said.

Close to 5 percent of patients had biomarkers that could inform their treatment, such as defects in DNA repair genes, which can be treated with PARP inhibitors, and mutations in mismatch repair gene defects that can be used to prescribe immunotherapy. Significant proportions of patients with rare tumors had pathogenic variants, such as 20 percent of sarcomas, 17 percent of hepatobiliary cancers, and 16 percent of cancers of unknown primary. Cobain highlighted that some of these patients with these rare tumors had germline mutations that could potentially be therapeutically targeted, which is important given the limited treatment options in these settings.

Ultimately, 11 patients received PARP inhibitors and immunotherapies based on germline findings. Two patients had a complete response, one had a partial response, and five had stable disease. Of the three patients who had progressive disease, two were breast cancer patients with germline ATM mutations treated with PARP inhibitors, and the third was a pancreatic cancer patient with a BRCA1 mutation who received a PARP inhibitor.

The results of this study "support consideration of directed germline testing in all patients with metastatic solid tumors to identify defects in DNA repair with therapeutic targets," Cobain said.

Needs infrastructure

To Funda Meric-Bernstam from MD Anderson Cancer Center, both of these studies demonstrate that if cancer centers are doing tumor/normal sequencing and looking for germline variants of clinical significance, they may not have to look too hard. However, she clarified that its also not "easy" to identify and report germline variants in this context. "This requires a lab to both analyze the normal [samples] and call pathogenic and likely pathogenic variants," she said.

Currently, there isn't a standardized method among tumor sequencing labs when it comes to dealing with germline findings. Some labs conduct only tumor testing, others conduct tumor-normal analysis but subtract germline findings, and still others perform tumor-normal testing and report only a subset of germline findings. Even if a lab sequencing only tumor tissue, tests will identify mutations in genes that are more likely to have occurred in the germline.

Meric-Bernstam noted that although the studies at MSK and the University of Michigan were done under IRB-approved protocols, in the real world when tumor sequencing is done, most patients aren't asked if they want to learn germline findings. "You really need infrastructure to return [results], to counsel, and to offer cascade testing," she said. "You need to facilitate the analysis of normal [samples] so you can ensure findings can be acted upon in a timely fashion, especially in patients with advanced disease. You need to have infrastructure in place for treatment matching and treatments available."

Though there are technical and infrastructural challenges to reporting out germline findings in the context of cancer tumor sequencing, genetics experts are increasingly of the opinion that it is no longer ethical to mask these findings, particularly given their increasingly important role in therapy selection as demonstrated by the ASCO studies. The American College of Medical Genetics and Genomics last month published a set of points that clinicians and genomics labs should consider when presumed germline variants are flagged during tumor sequencing.

Recognizing the varying practices in the field in this regard, the ACMG in its publication told genetic testing labs to be transparent about their ability to detect germline variants from tumor testing, as well as their reporting practices. Additionally, the ACMG told clinicians to take the opportunity when ordering tumor testing to evaluate the patient for clinical signs of an underlying hereditary cancer syndrome that may require germline testing.

According to Douglas Stewart, who is lead author of the ACMG paper and is a senior investigator within the National Cancer Institutes' Division of Cancer Epidemiology and Genetics, Clinical Genetics Branch, the aim of the association is to promote best practices. But it is also the association's hope, he recently said in an interview, that the issues laid out in the paper will start a discussion in the field about how "to capitalize on this huge opportunity of identifying germline variation in tumor sequencing so that it benefits as many people as possible."

Excerpt from:
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients - Precision Oncology News

Cheetahs are majestic cats found in parts of Asia and Africa. Centuries ago, these magnificent runners roamed the Indian subcontinent, before they were forced into extinction by humans. They were hunted, kept captive and used by the Maharajas for hunting other animals, and by the mid-twentieth century, they became locally extinct. Today, in parts of Africa and Asia where these cats are found, the destruction of their habitatgrasslandsare threatening the surviving populations of wild cheetahs. In Iran, for example, the wild population of Asiatic cheetahs are struggling.

In a bid to reintroduce cheetahs in India, suggestions were made to bring in African cheetahs from Namibia to Indian forests. After a prolonged legal battle, in January 2020, the Supreme Court allowed the reintroduction of these foreign cheetahs. This move is thought to bolster conservation and tourism. But such decisions cannot be based on the rule of the land alone. One needs to have sufficient information and understanding of several aspects, including the evolution and genetics of cheetahs in a region, to succeed in such efforts.

Previous studies have shown that the now-extinct Indian cheetah was an Asiatic subspecies. However, we do not know how closely the Asiatic and African cheetahs are related. Now, a study published in the journal Scientific Reports has probed the evolutionary relationship between cheetahs. The study, consisting of a team of international researchers, included those from the Centre for Cellular & Molecular Biology (CCMB) Hyderabad, the Birbal Sahni Institute of Palaeosciences, Lucknow, and the Zoological Survey of India (ZSI), Kolkata.

The researchers started by sequencing the mitochondrial DNA fragments, present outside the nucleus of a cell in an organelle called mitochondria, of an Indian cheetah and two African cheetahs. The African cheetah samples came from Southeast Africa and Northeasteast Africa, which were imported to India at different times. These three sequences were then compared against 118 published cheetah mitochondrial DNA sequences from various regions of Africa and Asia.

Based on previous studies, it was believed that the Asiatic subspecies of cheetahs diverged from the African subspecies only 5000 years ago. However, the genetic analysis of the current study found that this divergence is older than thought, and may have happened about 72,200 years ago. As a result, the populations today are genetically very different from each other, say the researchers, explaining the genetic uniqueness of Asiatic cheetahs. The study also found that the Asiatic cheetah and the Southeast African are more closely related to one another than to Northeast African cheetah.

The current study also sheds some insights into the origin of all cheetahs using the genetic analysis. It suggests that the common ancestor of all cheetahs is approximately 1,38,900 years olda number that is twice the previous estimate of 67,000 years.

The findings not only inform us about the evolutionary history of the cheetahs but also provides grounds on making an informed choice for their conservation. Phylogenetics, the study of evolutionary relationships, shows the differences in the genetic traits and characters and evolutionary history among species. The unique genetic makeup seen in these subspecies of cheetah not only help differentiate the populations from each other but also help determine their capacity to adapt to changing conditions.

In India, the results of the study have implications on what subspecies of cheetahs should be reintroduced. Some argue that reintroducing cheetahs could be a misplaced priority right now since Indias lions and tigers are in greater peril. Others opine that with the reintroduction, the countrys grasslands may be saved. The debate is still wide open, and science may soon help resolve it.

More here:
New insights on the evolution of cheetahs may help decide the best move on reintroduction - Research Matters

Point of Care Molecular Diagnostic Device Market was valued at USD635.5 million in 2018 and is estimated to grow at a CAGR of XX% from 2018 to 2026.Point of Care Molecular Diagnostics Device Market, By RegionA point-of-care (POC) test is performed at or near the site where a patient initially encounters the health care system. It has a rapid turnaround time (approximately 15 min) and provides actionable information that can lead to better patient management.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/10995/

Some of the key market drivers include the increasing technological advancements, ability to diagnose infectious diseases at sites with a limited infrastructure, availability of clinical evidence for the safety and efficacy procedures, patients awareness about better healthcare options and readiness for rising healthcare expenditures, changing technology and innovation, changing demographics and lifestyles leading to an increased prevalence of peripheral vascular diseases, adoption of new products, rising demand for advanced medical instruments, geriatric population.

Point of Care Molecular Diagnostics Device Market is segmented by product & service, technology, application, end user, and region. Point of Care Molecular Diagnostics Device Market has the largest usage in Physician Offices, Hospital Emergency Departments & Intensive Care Units, and Research Institutes

Geographically, global point of care molecular diagnostics device market is classified into North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW). In 2018, North America is anticipated to have the largest share in the global adhesion barrier market. The largest ratio of the North American market can mostly be attributed to the high prevalence of technologically advanced medical framework, sophisticated insurance & co-payment system & high R&D investment by governments and private funding organizations for the development of POC MDx tests are major factors responsible for the regions dominant market position. Availability of clinical evidence for the safety and efficacy of point of care molecular diagnostics procedures, transmuting technology and innovation.

Asia Pacific market is expected to grow at the fastest rate during the forecast period owing to the increasing demand for POC test. Many minuscule players are looking forward to investment in the Asia Pacific market due to sizable patient pool and incremental utilization of global adhesion barrier market devices.

DO INQUIRY BEFORE PURCHASING REPORT HERE:https://www.maximizemarketresearch.com/inquiry-before-buying/10995/

The key players in the Point of Care Molecular Diagnostics Device Market include Roche Diagnostics (Switzerland), Biomerieux (France), Danaher (US), Abbott Laboratories (US), Quidel (US) and Meridian Bioscience (US).

The years that have been considered for the study are:

Base year 2017 Estimated year 2018 Forecast period 2018 to 2026

Target Audience: POC Molecular Diagnostics Manufacturers Physicians Research Institutes Diagnostics Suppliers Market Research and Consulting Firms Regulatory Bodies Venture CapitalistsPoint of Care Molecular Diagnostics Device Market- Key Segment:

Point of Care Molecular Diagnostics Device Market, By Product & Service:

o Assays & Kitso Instruments/Analyserso Services & SoftwarePoint of Care Molecular Diagnostics Device Market, By Application:

o Respiratory diseaseso STDso HAIso Oncologyo HepatitisPoint of Care Molecular Diagnostics Device Market, By Technology:

o RT-PCRo INAATo Others Technologies Point of Care Molecular Diagnostics Device Market, By End User:

o Physician Officeso Hospital Emergency Departments & Intensive Care Unitso Research Instituteso Other End User

Company Profiles:

Abacus Diagnostica Advanced Liquid Logic (Illumina) Ahram Biosystems Akonni Biosystems Alere (Abbott) Amplino Analytik Jena Aquila Diagnostic Systems Atlas Genetics Axxin Becton, Dickinson & Co. (BD) Biocartis Biomeme bioMrieux Canon BioMedical Cepheid Coris BioConcept Coyote Bioscience Curetis DestiNA Genomics Diagnostics For All Diagnostics for the Real World DiaSorin DiAssess DNA Electronics DxNAPoint of Care Molecular Diagnostics Device Market, By Region

North America U.S Canada

Europe Germany France UK Italy Spain Russia Rest of Europe

Asia Pacific Japan China India South Korea Australia Rest of Asia Pacific

Rest of the World (ROW): Middle-East Africa Latin America

MAJOR TOC OF THE REPORT

Chapter One: Point of Care Molecular Diagnostics Device Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Point of Care Molecular Diagnostics Device Market Competition, by Players

Chapter Four: Global Point of Care Molecular Diagnostics Device Market Size by Regions

Chapter Five: North America Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Six: Europe Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Seven: Asia-Pacific Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Eight: South America Point of Care Molecular Diagnostics Device Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Point of Care Molecular Diagnostics Device by Countries

Chapter Ten: Global Point of Care Molecular Diagnostics Device Market Segment by Type

Chapter Eleven: Global Point of Care Molecular Diagnostics Device Market Segment by Application

Chapter Twelve: Global Point of Care Molecular Diagnostics Device Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Point of Care Molecular Diagnostics Device Market Report at:https://www.maximizemarketresearch.com/market-report/point-of-care-molecular-diagnostics-device-market/10995/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Connect With us at LinkedInLinkedIn

Connect with us at FacebookFacebook

Contact With Us at TwitterTwitter

See more here:
Point of Care Molecular Diagnostics Device Market Industry Analysis and Forecast (2019 to 2026) by... - Azizsalon News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Hunter Syndrome Treatment market.

Trusted Business Insights presents an updated and Latest Study on Hunter Syndrome Treatment Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Hunter Syndrome Treatment market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Hunter Syndrome Treatment Market

The global Hunter syndrome treatment market size was valued at USD 864.9 million in 2018 and is expected to witness attractive growth over the forecast period. Introduction of novel therapies, robust product pipeline, rising government initiatives, and increasing awareness regarding Hunter syndrome and its available therapeutic options are expected to significantly fuel the market growth over the forecast period.Hunter syndrome, also known as mucopolysaccharidosis type II (MPS II), is a rare genetic disorder caused by an iduronate-2-sulfatase enzyme deficiency. Presently, there is no permanent cure for Hunter syndrome. Existing treatment including enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) focuses on providing symptomatic relief and management of complications associated with the disease progression.

According to the data published by the National Institute of Health (NIH) in 2018, Hunter syndrome affects around 1 in 160,000 males globally. The risk of developing this disease is far less among women because they inherit two X chromosomes and one of them can provide a functioning gene if the other X chromosome is defective. However, in men, there is no other X chromosome to compensate for the defective one.Expected approval of novel therapies in late-phase clinical trials and increasing R&D activities by key players for the development of such novel therapies are anticipated to be two major factors driving the market growth in the near future. For instance, in June 2019, Denali Therapeutics Inc. received FDAs Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation for its pipeline drug candidate DNL310, which is being evaluated for the treatment of the disease.Initiatives undertaken by various organizations for creating awareness regarding the disease diagnosis and its treatment is expected to support market growth over the forecast timeframe. For instance, in May 2018, Shire Plc. in collaboration with the National MPS Society and International MPS Network launched its third #FlyforMPS digital campaign aimed to increase awareness about .Treatment InsightsBased on treatment type, the market is categorized into enzyme replacement therapy (ERT), hematopoietic stem cell transplant (HSCT), and others. In 2018, the ERT segment accounted for the largest market share and is anticipated to hold onto its dominance over the forecast period. This is attributed to improved sales of Shire Plcs ELAPRASE and a potential for worldwide approval of GC Pharmas product called Hunterase.

Shire Plcs Elaprase (idursulfase) is the single major drug used for the treatment of Hunter syndrome, with GC Pharmas Hunterase (idursulfase beta) being approved only in South Korea as of now. These drugs have addressed a significant unmet need. However, the high cost of these drugs is expected to be a major factor hindering their market growth. For instance, Idursulfase (Elaprase) drug costs around USD 3,100 per 6mg/3ml vial.

Regional Insights of Hunter Syndrome Treatment Market

In 2018, North America dominated the market owing to favorable regulations for orphan drug development, rising awareness among people concerning rare diseases, increased funding for research activities, and improved healthcare facilities. Furthermore, the favorable reimbursement policies for expensive drugs such as ELAPRASE in the U.S. have supported its adoption and fueled the regional growth.Asia Pacific region is projected to exhibit a lucrative growth rate over the forecast period. Japan, China, and India are expected to emerge as potential countries for growth, owing to their high unmet needs in the market. Major players are focused on gaining approval for their novel therapies and are penetrating these markets to attain a major share. For instance, in July 2019, CANBridge Pharmaceuticals Inc. filed a New Drug Application (NDA) with the National Medical Products Administration (NMPA) for its novel treatment drug called Hunterase in China. Hunterase (idursulfase beta) is a patented therapy of GC Pharma indicated for the treatment of Hunter syndrome.

Market Share Insights of Hunter Syndrome Treatment Market

Some of the key players in the market comprise Shire Plc. (Takeda Pharmaceutical Company); GC Pharma; JCR Pharmaceuticals Co Ltd.; RegenxBio Inc.; Sangamo Therapeutics, Inc.; ArmaGen Inc; Inventiva S.A.; Denali Therapeutics Inc.; Bioasis Technologies Inc.; and Esteve.Currently, Shire Plc. (acquired by Takeda Pharmaceutical Company Limited in April 2019) is a prominent market player, with strong sales of its drug ELAPRASE, indicated for the treatment of Hunter syndrome. However, Shire plc is expected to face stiff competition from Green Cross (GC) Pharma over the forecast period. GC Pharma is emerging as a global player in the Hunter syndrome treatment market with its orphan drug, Hunterase.GC Pharma is undertaking inorganic growth strategies such as partnerships and collaborations for the commercialization and geographical expansion of Hunterase. For instance, in April 2019, Clinigen Group plc and GC Pharma entered into an exclusive licensing agreement under which Clinigen gained the rights to commercialize Hunterase in Japan.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Hunter Syndrome Treatment Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, this market research report has segmented the global Hunter syndrome treatment market report on the basis of treatment and region:

Treatment Outlook (Revenue, USD Million, 2019 2030)

Enzyme Replacement Therapy (ERT)

Hematopoietic Stem Cell Transplant (HSCT)

Others

Quick Read Table of Contents of this Report @ Hunter Syndrome Treatment Market Size, Share, Market Research and Industry Forecast Report, 2026 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Read more:
Hunter Syndrome Treatment Market Analysis Of Global Trends, Demand And Competition 2020-2028 - 3rd Watch News

More than two million people in England still won't be able to see friends and family when lockdown rules are eased this weekend.

Rules are changing across the UK - with different numbers of people now allowed to meet up England, Wales, Scotland and Northern Ireland.

But for the 2.16million people told to 'shield' because they are clinically vulnerable, the rules won't change for some time.

George Eustice has warned that those shielding from coronavirus may have to continue to do so for several more months.

Asked about ways to make life easier for those who are shielding, the Environment Secretary told LBC: Well it is something that we are looking at because we completely recognise that those who are shielded and clinically vulnerable who have been told to isolate and not to see friends and family at all, that is going to start taking its toll on them and we want to be able to find ways to be able to do that.

But it is very, very difficult because they are clinically vulnerable and nobody obviously wants to visit family in that group and find that theyve given them the virus.

So we dont have answers yet, thats why they have to remain shielded for the time being, possibly for several more months.

He added that it is a difficult situation with that shielded cohort.

According to the NHS, if you have been identified as needing shielding - if you are at high risk of developing complications - you will have received a letter from your GP, hospital or (if identified nationally) from the national helpline.

Where the NHS holds a mobile number it will have also sent you a series of SMS text messages. These will come from either 07307 810357 or UK_Gov. If you are unclear why you have received a letter, contact your GP or hospital consultant.

You should register yourself on the gov.uk website if you need extra help and support. If you do not register on the website, then you will be contacted by the shielding helpline to confirm that you do not need support.

The call will be made from 0333 3050466. It is not a live telephone line, but if you call it you will get the recorded message: You were called today by the Shielding Helpline, sorry that we missed you, there is no need to call us back as we will try again soon. Thank you, goodbye.

Patients are at moderate risk of developing complications from coronavirus (COVID-19) where:

This includes the following patient groups:

Here is the original post:
Millions of people won't be able to see family for months says minister - MyLondon

My wife and I can both roll our tongues but our son can't. I'm worried about his paternity (Photo: Shutterstock)

I am a 36-year-old woman and have no children, but I am planning on having some in a few years. Is it true that with advancing age I increase my chances of getting a child with Downs syndrome or cerebral palsy?

ALSO READ: Ask the doctor: Covid-19 in children: What do we know?

Yes, these conditions have been associated with problematic pregnancies and abnormal foetal development. After age 35, older eggs tend to have abnormal cell division where the chromosomes may fail to separate in the correct way, leading to an excess number of expected chromosomes.

For example, in Downs syndrome, the foetus has an extra chromosome resulting in what is referred to as trisomy. Cerebral palsy is associated with complications of advanced parental age, especially the mothers. These may include miscarriages, multiple births, high blood pressure, gestational diabetes, and genetic mutations that impact brain development. Studies have also suggested that an older couple is more likely to use infertility procedures that can increase the risk of multiples and other risk factors.

I discovered that my fiances sister has albinism. How likely is it that any of our future children develops the condition?

There is a 50 percent chance your fiance is a carrier for the albinism gene. If this holds true, then there is a 25 percent chance that your future children may develop this condition.

My wife can roll her tongue (the rolling tongue gene). So can I. But our son, now 4, cant. I am worried about my childs paternity but dont want to stir the marriage yet. Do you think I should be worried or is there a genetic explanation?

There should be no cause to worry. More recent studies disputed the misleading assumption that leads to the conclusion that is worrying you. There was a study on identical twins who differed in their tongue-rolling trait, suggesting that the trait was not entirely under genomic influence as identical twins have the same genetic makeup.

I hope to get a child through a sperm bank. Do you think my request for physical characteristics of the sperm donor will help towards getting desirable traits in my future child?

ALSO READ: Ask the doctor: Is penile enlargement surgery considered plastic surgery? Does it work?

Yes, most physical characteristics are easily inherited from parents to their offspring. However, this could be a mixture of traits from both the donor and the recipient.

How far is the world from genetically engineering desirable traits into people and consequently having designer babies?

It is already happening on a smaller scale for certain traits, for example women or men going to sperm banks look for super straights in their donors for IVF procedures.

The world is also moving towards precision medicine, or what is commonly known as personalised medicine where everyone has their medicine tailor-made to suit their genes and condition based on their genetic fingerprint.

With technologies such as CRISPR/Cas9 gene editing, the future of designer babies is possible although ethical considerations in human cloning restrict such practices and may fail to promote advancements in these technologies.

Can I influence my childrens personalities or are they predetermined before birth?

To some extent yes, but personality is influenced by various factors. One component may come from the genes and the other from environmental interactions. For example, exposure to different life circumstances greatly influences ones personality.

ALSO READ: Why its better to have children before your 40s

My four-year-old twins are very different. My son has a real mean streak. Hes always been like that. His sister is kind. I have been responsible for their upbringing so far. Are character traits in the genes?

The difference could be in their genetic makeup. As we know, we inherit half of our genes from each parent and different personality traits could arise from this. In addition, the contrast in their personality could emanate from their daily interactions with the external world, such as from observations.

For More of This Stories Subscribe to the Standard Epaper to get a copy of Eve Woman in the Standard

You also have not told us if you treat the children differently whereby in most cases girls are treated kindly with lots of pampering, which is thus reflected in their behaviour. Boys who are often groomed to harden up to face the real world like men and turn out as brave warriors.

As a geneticist, do you think psychopaths are born or made?

I think it is a mixed bag of fortunes here. Psychopaths could result from nature and nurture. Several studies have pointed to the existence of genetic abnormalities in psychopaths, whereas other cases have risen purely from their upbringing. For example, we have had cases of sociopathic behaviour arising after traumatic experiences and drug addiction.Couples can undergo genetic testing to determine if they have any conditions their children can inherit (Photo: Shutterstock)

I have read a bit about genetic testing for couples, and I am considering it before we start a family. My question is, if they find something worrying (my sister died of sickle cell anaemia) can it be prevented because we know beforehand?

It may not be prevented in its entirety, but may help in early management of the outcome. It may also help in decision making whether to proceed and have children in the full knowledge that they may develop an inherited condition from parents. For your case, you could be a carrier for sickle cell disease and this prepares you to seek genetic therapy such as stem cell transplants to correct the abnormal red (sickle) cells.

I did the BRCA gene test and I have the mutated gene. What are the chances I could get ovarian or breast cancer?

A mutated BRCA gene is only an indicator of higher risk of developing either ovarian or breast cancer. It does not mean that you already have the cancer. It helps you prepare to seek and make a plan for testing and monitoring of signs of the development of these cancers so that preventative or management measures can be instituted. This may help in following a lifestyle that can reduce the chances of accelerating the development of the disease.

Is there a genetic explanation as to why children, especially firstborns, look like their fathers?

Well, it is not always the case. Physical characteristics of the offspring sometimes might be a mixture of both the mothers and fathers characteristics. There are, however, extremes where a child may look like a copy of either parent. A child is a result of the union of genes of a mother and father, and the strength of expression of these genes may differ.

There is conflicting information out there about genetically modified foods. What are the facts and fiction on this?

Genetically modified foods refer to food items whose source material production, be it plant or animal, involves intentional mixing (manipulation) of genetic material not naturally found in the pure/natural breed.

The fuss brought about by anti-GMO campaigners has been related, in my opinion, to a lack of information. The genes being included have their function known from a science point of view. However, genes may interact and the results may not be known fully. How a gene will behave in the new organism is assumed to be what is known, but it does not rule out undesired effects. However, before a gene is used in GMO, experimental tests are usually performed to understand different scenarios under which it may elicit undesired effects.

Dr Fredrick Nindo, a geneticist, is a visiting post-doctoral research fellow at the Mediterranean Infection Institute for Research in Cancer and Ageing, France.

Do not miss out on the latest news. Join the Eve Digital Telegram channel HERE.

Excerpt from:
Ask the doctor: Is there a chance I am not my sons father? - The Standard

Other Applications

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Personalized Medicine market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=254994&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=254994&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Personalized Medicine Market Size, Personalized Medicine Market Trends, Personalized Medicine Market Growth, Personalized Medicine Market Forecast, Personalized Medicine Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

Originally posted here:
Personalized Medicine Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Precision Medicine market.

Trusted Business Insights presents an updated and Latest Study on Precision Medicine Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Precision Medicine market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Abstract, Snapshot, Market Analysis & Market Definition: Precision Medicine MarketIndustry / Sector Trends

Precision Medicine Market size was valued at USD 52.6 billion in 2018 and is expected to witness 10.5% CAGR from 2019 to 2025.

U.S.Market Segmentation, Outlook & Regional Insights: Precision Medicine Market

Precision Medicine Market, By Technology, 2018 & 2025 (USD Million)

Growing demand and advancements in cancer biology will drive personalized medicine market during the forecast period. Accessibility to large-scale human genome database including next-generation sequencing (NGS) and computational tools foster industry growth. Development of innovative genetic technologies examines the functional effect of genetic makeup that leads in developing cancer, thus, should propel huge demand for cancer biology. Several such tools are widely used to study the mechanism of DNA repair, epigenetic changes related to cancer and gene regulation in cancerous cells that offer opportunities for cancer biology in personalized medicine.

Moreover, improving efficiencies within the health care system will serve to be positive impact rendering factor personalized treatment business growth. Benefits offered by personalized medicines and treatment includes target treatment for patient, optimal dosing, focus on prevention and earlier intervention as well as preventing adverse events. Thus, above mentioned features will foster the demand for personalized medication market growth. However, high cost associated with precision medicine may impede industry growth over the forecast period.

Precision Medicine Market, By Technology

Drug discovery segment held over 21% revenue share in 2018 and is projected to grow significantly by 2025. Focus of business players on developing technologically advanced drugs enabling superior treatment for several life-threatening diseases will create segmental growth opportunities. Bio-pharmaceutical companies utilize bioinformatics software to introduce customized novel drugs that should augment the segmental growth.

Gene sequencing segment is anticipated to show exponential CAGR of around 11% over the coming years. Benefits offered by gene sequencing technique such as relevant information about patients genome and biological research ensures quick drug discovery process that should boost segmental growth.

Precision Medicine Market, By Application

Immunology segment accounted for over USD 9.5 billion in 2018 and is estimated to witness considerable growth trend during the analysis period. Growing demand for bioinformatics and big data analytics to segregate human genome data obtained from immunological processes favors segmental growth.

Oncology segment held significant revenue share in 2018 and is assessed to show more than 10.5% CAGR during the forecast period. Segment growth is attributable to increasing prevalence of cancer cases resulting in development of innovative drugs with specific drug formulations in precision medicine.

Germany Precision Medicine Market Size, By Application, 2018 (USD Million)

Precision Medicine Market, By End-use

Healthcare IT companies segment held more than 27% revenue share in 2018 and will show lucrative growth over coming years. Increasing demand for developing technologically advanced tools for rapid integration, storage, and analysis of patient data should augment the business growth.

Diagnostic companies segment was valued around USD 9.5 billion in 2018. Such companies provide solutions that bridges the gap between clinical needs of patients and technology. Various benefits such as high quality of the medical diagnostic devices enabling precise patient management will foster industry growth.

Precision Medicine Market, By Region

North America precision medicine market is predictable to show around 9% CAGR over the analysis period. Rising prevalence of respiratory and oncology diseases as a result of lifestyle changes is the key factor driving demand for market. Rising healthcare expenditure coupled with presence of major industry players in North America will spur the business growth.

Asia Pacific precision medicine industry was valued more than USD 11 billion revenue in 2018. Regional growth can be attributed to technological advances in sequencing technology. Moreover, presence of large patient pool in Asia Pacific along with growing investments in R&D activities will accelerate personalized medication business growth.

MEA Precision Medicine Market Size, By Country, 2025 (USD Million)

Key Players, Recent Developments & Sector Viewpoints: Precision Medicine Market

Few of the prominent industry players operating in precision medicine industry include Biocrates Life Sciences, Tepnel Pharma Services, Qiagen, Menarini Silicon Biosystems, Novartis, NanoString Technologies, Pfizer, Eagle Genomics, Quest Diagnostics, Roche, Intomics, and Teva Pharmaceutical. The business players implement several strategies including acquisitions, partnerships and innovative product enhancement to capitalize on market growth opportunities.

Recent industry developments:

In October 2018, Eagle Genomics partnered with Microsoft Genomics to tackle computational challenges of genomics era. This partnership aimed to inculcate scale and power of cloud to precision medicine, across the production of fundamental research and core services.

In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine to more patients.

Precision Medicine Industry Viewpoint

History of precision medicine can be tracked back in 1950s when Watson and Crick discovered the structure of the DNA as double-helix. Efforts to supplement the DNA structure, researchers cracked the genetic code in early 1960s. Additionally, introduction of the first DNA sequencing technology was developed in 1970s where researchers discovered first enzyme linked to individual variation in response to dosing. In early 1980s Polymerase Chain Reaction (PCR) was first discovered allowing for fast amplification of DNA sequences. These advances continued in 1990s where human genome project was launched along with FDA approval for first personalized medicine with a companion diagnostic, for the treatment of HER2 positive breast cancer. Such form of advancements continued in 2000s where first targeted therapies for lung cancer, leukemia, melanoma, cystic fibrosis, HIV, and other diseases accelerated tremendous growth opportunities for precision medicine. Moreover, increasing demand for personalized medication for secured patient management will drive industry growth during the forthcoming years

Key Insights Covered: Exhaustive Precision Medicine Market1. Market size (sales, revenue and growth rate) of Precision Medicine industry.2. Global major manufacturers operating situation (sales, revenue, growth rate and gross margin) of Precision Medicine industry.3. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Precision Medicine industry.4. Market size (sales, revenue) forecast by regions and countries from 2019 to 2025 of Precision Medicine industry.

Research Methodology: Precision Medicine Market

Quick Read Table of Contents of this Report @ Precision Medicine Market Research Report Forecast to 2029 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Precision Medicine Market Overview By Growing Demands, Trends And Business Opportunities 2020 To 2027 - Cole of Duty

Abraham Maslow said in 1966, I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail. This mentality known as the Law of the Instrument indicates that people tend to rely on the tool with which they are most familiar.

In a healthcare setting, that can translate into only using traditionally trained medical professionals to handle every situation, but in reality, some issues require a collaborative approach that includes other skills and experience. This is particularly relevant when it comes to addressing social determinants of health (SDoH).

Social determinants of health can include many things: food, housing and transportation insecurities; lifestyles, locations and surroundings; social isolation; and other factors that prevent people from achieving and maintaining good health. Non-clinical influences like these can drive up to 80% of clinical outcomes, affecting an individuals ability to be healthy.

In other words, it takes more than the latest treatments to keep people healthy. Much work is being done to address social determinants at the public health level, but these factors must also be addressed at the patient level. The paradox about population health is that its all about individuals and using a collaborative approach can be the key to success.

Why the Collaborative Approach WorksStudies indicate that patients who perceive their providers as more empathetic tend to get better more quickly, and experience less severe symptoms. Yet providers sometimes lack the capacity to treat patients holistically, or the data and insights to understand why a patient isnt taking their medicine, even though insights into social barriers can guide how providers should interact with patients.

Educating a patient is helpful, but typically not effective at changing behavior, especially when social factors are at work. Additionally, people trained in the medical field are not also trained and resourced to deliver interventions involving social factors.

This is where an interdisciplinary team approach can help to improve population health by addressing social determinants at the individual level. The best approach to care involves a team that includes a range of medical professionals, social workers, behavioral health specialists and community health coaches, all working together to formulate and deliver a comprehensive support plan tailored to each patients priorities and needs.

Instead of telling patients what to do, local care teams can work with patients to understand their barriers, such as lack of transportation or housing insecurity, and tap local resources to reduce or remove them. By simply asking the right questions, community health coaches can get much more tactical and concrete about supporting the individual and tailoring treatment support plans.

Additionally, these coaches often live in the same community and understand the context of peoples lives, which improves communication and creates trust. In fact, Medicaid members who receive community-based services are less likely to be admitted to the ER or as an inpatient in a hospital. During one-on-one interactions, community health specialists are well-positioned to understand the social roadblocks to access care and adhering to treatment plans.

A collaborative team is ideally suited to assess the social and environmental factors impacting a persons health, identify barriers of care, and create a personalized support plan that may include services such as behavioral health support, patient advocacy, and remote monitoring technology to remove those barriers and improve care plan adherence.

The Four Components of SuccessA successful strategy to address social determinants of health comprises four components:

Analytics: In any population health intervention, the team needs to identify through stratification who is at the greatest risk, to properly titrate the resource intensiveness of an intervention. If you try to intervene equally with everyone, your efforts (and funds) will be spread too wide and too thinly.

Using analytics on the front end can ensure that the people with the highest risk are receiving more intensive treatments. Healthcare teams can look to existing data sets like consumer marketing data, which often is a treasure trove of information on factors that affect health such as transportation, housing issues and financial stress. For example, data can reveal if an individual lives alone, owns a car, or lives near public transportation all factors that impact a persons ability to follow through with their care plan. These insights can be integrated with data on medical risk and cost of care before the amalgamated data set is stratified.

A multidisciplinary support team: As stated, for social determinants to be addressed on an individual level requires an integrated team of both clinical and social support experts and community-based coaches are essential contributors.

The right toolbox from which to draw: There are existing toolboxes of interventions for housing, food insecurity and stress management, and the care team should recognize what needs to be addressed and draw from existing strategies to address healthcare at the social level. Interventions that mitigate the social stressors impacting an individual around the clock provide the greatest health benefits.

Respect for the individuals priorities: A population health team must have the flexibility to prioritize what the individual sees as the greatest issue. For example, a homeless individual might have a substance use disorder (SUD). Typically, people with SUD cannot get into housing until they are in recovery; however, if the individual is not ready to work on their recovery, but does see stable housing as a stepping stone toward recovery, that should be respected so work first on what theyre ready to work on.

A Better Approach to Addressing Population HealthWhile the use of multidisciplinary teams can involve significant changes to work practices and organizational arrangements, providing community-based resources is essential to addressing social barriers that affect health and wellness.

By understanding the social factors that can impact patient wellness, and employing a collaborative approach to individual care, payers, providers and patients will reap the benefits of more successful outcomes improving population health overall.

Photo: marchmeena29, Getty Images

See the original post here:
The paradox of population health: Focus on personalized support for the greatest impact - MedCity News

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced that it will expand its robust menu of ready-to-use Simoa kits to include tau phosphorylated at threonine 181 (p-tau181), a highly specific biomarker for the study of Alzheimers disease pathology, in cerebral spinal fluid (CSF), serum and plasma. A growing body of research, including work published recently in The Lancet Neurology, suggests that the biomarker could prove critical to predicting Alzheimers disease progression and differentiating the disease from other neurodegenerative disorders. Moreover, an ultra-sensitive, blood p-tau181 assay may hold the key to advancing preventative care for the disease in clinics and via homecare sampling through a simple, cost-effective blood-based screening that can deliver an early, objective diagnosis. These findings and details on how researchers can gain early access to Quanterix new commercial assay through the Simoa Accelerator Laboratory, will be discussed during an upcoming Powering Precision Health (PPH) Think Tank Webinar taking place at 10 a.m., EDT on June 3, 2020.

Biomarkers continue to play an invaluable role in understanding how neurological diseases manifest, progress and respond to treatment, said Kevin Hrusovsky, Chairman, Chief Executive Officer and President, Quanterix. Building on years of innovation and a proven track record for successfully commercializing ultra-sensitive assays that disrupt markets and drive innovative breakthroughs forward, our p-tau181 version 2 assay kit offers researchers unrivaled visibility and specificity into this revolutionary marker in serum and plasma. The exquisite sensitivity of Simoa uniquely positions us to deliver on the promise of p-tau181 to pave new pathways in Alzheimers disease exploration, just as our neurofilament light chain (Nf-L) assay has transformed research for other neurological diseases. In particular, the impact of a high-definition, blood-based Simoa assay that rivals traditional CSF or PET scans could be revolutionary, with material potential for home sampling to enable early detection and development and approval of drug therapies desperately needed to improve outcomes for the millions of people living with Alzheimers disease today. This biomarker advance fits perfectly in our vision to transform reactive sick care' into proactive asymptomatic precision healthcare.

While deaths associated with other pervasive diseases such as heart disease have declined between 2000 and 2018, Alzheimers disease-related deaths have increased by 146 percent, according to the Alzheimers Association. Importantly, there is no objective test to diagnose the disorder, leading many physicians to rely solely on subjective cognitive assessments. As a result, many patients are not diagnosed until late in the diseases progression, after symptoms of cognitive decline, such as memory loss, begin to present. Even then, the disease can often be misdiagnosed for another neurodegenerative condition, such as frontotemporal dementia (FTD).

For years, researchers have studied the utility of biomarkers for understanding, detecting and monitoring Alzheimers disease. These efforts have been accelerated in large part by the PPH network, which has grown into a global epicenter for biomarker-enabled innovations to not only detect and treat, but ultimately, prevent disease. Resulting studies demonstrate the vast utility of proteins such as total tau and Nf-L. Researchers, doctors and pharmaceutical companies are now harnessing these biomarkers to see the disease earlier, monitor its progression and inform clinical decision making more effectively, and assess the viability of experimental therapies. Quanterix ultra-sensitive immunoassay technology, Simoa, which empowers single- and multi-plex detection of key biomarkers with 1000 times greater sensitivity than competing enzyme-linked immunosorbent assay (ELISA) solutions, is the driving technology behind much of this research. Among the most notable is a 2019 Nature Medicine paper that used Simoa to see signs of Alzheimers disease 16 years before symptoms through the high-definition detection of Nf-L. The technology has powered hundreds of similarly peer-reviewed journals over the years that demonstrate the potential for blood-based detection of the disease with equal or greater sensitivity as compared to CSF or PET biomarkers. Collectively, these studies create an influential body of research that advances the preventative care paradigm envisioned by PPH at its inception by supporting the utility of a non-invasive and easily administered blood test to detect Alzheimers disease before symptoms.

Today, emerging research suggests that p-tau181 could hold even greater diagnostic promise for Alzheimers disease, as it has proven capable of differentiating the condition from other forms of dementia with greater specificity than total tau. Leaders in the field of neurodegenerative disease research, such as the authors of The Lancet Neurology paper Professors Henrik Zetterberg, MD, PhD, and Kaj Blennow, MD, PhD, of the University of Gothenburg, believe blood p-tau181 has the potential to revolutionize Alzheimers disease research and patient care in much the same way that serum-based Nf-L has for multiple sclerosis (MS).These concepts further progress PPHs mission and vision to harness biomarkers for true precision health, with myriad implications that include improving understanding of the condition, enabling earlier diagnosis and intervention, informing more accurate long-term care, identifying clinical trial candidates earlier in the disease cascade and, subsequently, accelerating promising new therapies to market.

The latest installment of the PPH Think Tank series of webinars, entitled Novel p-tau181 Blood Immunoassay and the Future of Alzheimers Disease Research, will explore the vast opportunities associated with p-tau181 to revolutionize the way we approach disease and administer care. Specifically, the discussion will detail how an innovative immunoassay to measure p-tau181 in blood could accelerate efforts to establish a clinically relevant routine Alzheimers disease diagnostic test, and the potential high-definition detection via small volume blood samples creates for homecare precision health. Hrusovsky, together with Professors Zetterberg and Blennow, will break down the findings from the recent paper in The Lancet Neurology and examine how Simoa is powering exploration into uncharted territory as it pertains to Alzheimers disease detection, monitoring, treatment and prevention.

Were on the cusp of what could be an incredible new era for Alzheimers patients and those with a genetic predisposition to the disease, said Zetterberg. The ability to see dementia asymptomatically and moreover conclusively distinguish it as Alzheimers disease-induced could forever change the face of this condition. P-tau181 shows immense promise in this regard, which is augmented considerably when harnessed by a leader in detection like Quanterix.

Early findings from our work with p-tau181 are very encouraging, said Blennow. The biomarker is proving to be an exceptional new tool in our arsenal against Alzheimers disease. While CSF p-tau181 has been recognized as a highly valuable biomarker in Alzheimers disease pathology, the greater clinical benefit will come from our ability to effectively harness the marker in blood. The unprecedented specificity of p-tau181 paired with a highly sensitive technology like Simoa promises to broaden our knowledge of this devastating disease considerably, with monumental implications for patients and caregivers.

To register for the webinar, click here.

To learn more about how you can take advantage of our early access program for p-tau181 through the Accelerator Lab or pre-order your commercial kits, visit https://www.quanterix.com.

For more about Quanterix Simoa technology, visit https://www.quanterix.com/Simoa-bead-technology.

About Quanterix

Quanterix is a company thats digitizing biomarker analysis with the goal of advancing the science of precision health. The companys digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

About Powering Precision Health

Powering Precision Health is the world's first independent, non-profit organization dedicated to bringing the world's leading physicians, scientists, innovators, investors and patient advocates together to unveil their latest research on new biomarkers that are revolutionizing precision health. Founded by Kevin Hrusovsky, a widely acclaimed thought leader and visionary in life sciences and personalized medicine, Powering Precision Health is a movement that represents the intersection of new technological capabilities with the latest medical research. Its rooted in the science of precision medicine, which shows personalized treatments to be an increasingly more effective way to maximize drug efficacy and minimize toxicity. In addition to the impact environmental and lifestyle factors can have on minimizing disease triggers, precision health marks an evolution in the way we approach disease and aims to inspire a full healthcare transformation, from philosophy to approach to outcome. In an industry often plagued by skepticism and marred by false promises, PPH puts science first and brings together stakeholders that span from fundamental research to clinical practice, investors, policy makers, patient advocacy groups, and anyone who embraces the vision of Powering Precision Health. Featuring a distinguished keynote lineup of dignitaries, the Summit unveils groundbreaking approaches to prevention, early diagnosis, and next-generation treatments. Powering Precision Health is supported thanks to the generous contributions of sponsors from a wide range of companies and organizations committed to advancing precision health.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

See more here:
Quanterix Expands Menu of Ultra-Sensitive Neurology Assays with Simoa P-Tau181 V2 Kit for Improved Detection and Study of Alzheimer's Disease -...

New Jersey, United States, The Personalized Medicine Market report examines the market situation and prospects and represents the size of the Personalized Medicine market (value and volume) and the share by company, type, application and region. The general trends and opportunities of Personalized Medicine are also taken into account when examining the Personalized Medicine industry. Personalized Medicine The market report focuses on the following section: Analysis of the Personalized Medicine industry by transfer into different segments; the main types of products that fall within the scope of the report.

This Personalized Medicine market report is a complete analysis of the Personalized Medicine market based on an in-depth primary and secondary analysis. The scope of the Personalized Medicine market report includes global and regional sales, product consumption in terms of volume and value. The Personalized Medicine market report contains an estimate of revenue, CAGR and total revenue. The knowledge gathered in world trade Personalized Medicine is presented in figures, tables, pie charts and graphics.

Get | Research Sample Copy By Using Corporate Mail ID @https://www.verifiedmarketresearch.com/download-sample/?rid=7106&utm_source=COD&utm_medium=007

Top 10 Companies in the Global Personalized Medicine Market Research Report:

Global Personalized Medicine Market: Drivers and Restrains

The research report included analysis of various factors that increase market growth. These are trends, restrictions and drivers that change the market positively or negatively. This section also contains information on various segments and applications that may affect the market in the future. Detailed information is based on current trends and historical milestones. This section also includes an analysis of sales volume on the Personalized Medicine market and for each type from 2015 to 2026. This section mentions sales volume by region from 2015 to 2026. The price analysis is included in the report Type of year 2015 to 2026, manufacturer from 2015 to 2020, region from 2015 to 2020 and total price from 2015 to 2026.

An in-depth assessment of the restrictions contained in the report describes the contrast to the drivers and leaves room for strategic planning. The factors that overshadow the growth of the market are essential as they can be understood to design different phrases to take advantage of the lucrative opportunities that the growing Personalized Medicine market offers. In addition, information on the opinions of market experts was used to better understand the market.

Global Personalized Medicine Market: Segment Analysis

The research report contains certain segments such as application and product type. Each type provides revenue information for the 2015-2026 forecast period. The application segment also provides volume revenue and revenue for the 2015-2026 forecast period. Understanding the segments identifies the importance of the various factors that support Personalized Medicine market growth.

Global Personalized Medicine Market: Regional Analysis

The research report includes a detailed study of the regions of North America, Europe, Asia Pacific, Latin America, the Middle East and Africa. The Personalized Medicine report was compiled after various factors determining regional growth, such as the economic, environmental, social, technological and political status of the region concerned, were observed and examined. Analysts examined sales, sales, and manufacturer data for each region. This section analyzes sales and volume by region for the forecast period from 2015 to 2026. These analyzes help the reader understand the potential value of investments in a particular region.

Global Personalized Medicine Market: Competitive Landscape

This section of the report lists various major manufacturers in the market. It helps the reader understand the strategies and collaborations that players focus on to fight competition in the market. The full report provides a significant microscopic overview of the Personalized Medicine market. Readers can identify manufacturers footprints by knowing manufacturers global earnings, manufacturers world market prices, and manufacturers sales for the 2015-2019 forecast period.

Ask For Discounts, Click Here @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7106&utm_source=COD&utm_medium=007

Table of Content

1 Introduction of Personalized Medicine Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Personalized Medicine Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Personalized Medicine Market, By Deployment Model

5.1 Overview

6 Personalized Medicine Market, By Solution

6.1 Overview

7 Personalized Medicine Market, By Vertical

7.1 Overview

8 Personalized Medicine Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Personalized Medicine Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @https://www.verifiedmarketresearch.com/product/global-personalized-medicine-market-size-and-forecast-to-2026/?utm_source=COD&utm_medium=007

About us:

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyse data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defence, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & construction, Agriculture industry and Medical Devices from over 100 countries.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll Free: +1 (800)-7821768

Email: [emailprotected]

See the article here:
Personalized Medicine Market Growth Analysis by Size, Top Companies, Supply Demand, Trends, Demand, Overview and Forecast to 2026 - Cole of Duty

SALT LAKE CITY, May 29, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, today announced the presentation of two new studies at the 2020 American Society of Clinical Oncology (ASCO) annual meeting demonstrating the ability of Myriads riskScore test to provide personalized breast cancer risk information that allows patients and physicians to make better informed clinical treatment decisions.

We are excited to further demonstrate Myriads commitment to providing the best possible risk assessment tools to patients through innovation, said Nicole Lambert, president of Myriad Oncology, Myriad Womens Health and Myriad International. The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.

Summaries of the studies are below. Follow Myriad on Twitter via @myriadgenetics and keep up to date with ASCO meeting news and updates by using the #ASCO20 hashtag.

riskScore Presentations at 2020 ASCO:

Title:Comprehensive breast cancer (BC) risk assessment for CHEK2 carriers incorporating a polygenic risk score (PRS) and the Tyrer-Cuzick (TC) modelPresenter:Mark E. Robson, MD, Memorial Sloan Kettering Cancer CenterLocation:https://meetinglibrary.asco.org/record/187438/abstract

In this study, 358,471 women with hereditary cancer risk who were tested with a multigene panel were assessed to find 4,331 women who were carriers of deleterious CHEK2 mutations. These patients were used to develop a mathematical model to assess risk status using family history information and Myriads riskScore test. This model was then validated in an independent cohort of 459 women. In CHEK2 pathogenic variant carriers, a significant correlation was detected of CHEK2 status with family history (FH) (p=4.1 10-17) and of polygenic risk scores with FH among CHEK2 carriers (p=1.7 10-5). Among the patients in the validation cohort, 24.0% of CHEK2 carriers were categorized as low risk (<20%), and 62.6% were categorized as moderate risk (20-50%). For 13.4% of CHEK2 carriers, risk estimation incorporating PRS and TC generated BC risks of greater than 50%, consistent with genes recognized as highly penetrant.

To view Graph 1: Precision Breast Cancer Risk Categorization of CHEK2 Carriers,please visit the following link:https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4a8828-8282-47df-9e4d-b82f11604b2b

Title:Performance of the IBIS/Tyrer-Cuzick (TC) Model by Race/Ethnicity in the Womens Health InitiativePresenter:Allison W. Kurian, M.D., M.Sc, Stanford UniversityLocation:https://meetinglibrary.asco.org/record/185965/abstract

In this study, 91,893 women of differing racial identities with no personal history of breast cancer were followed for a median of 18.9 years to assess incidence of breast cancer. 6,836 new cases of breast cancer were diagnosed among the women. The Tyrer-Cuzick model was used to assess risk of breast cancer and then actual cases of breast cancer were compared to expected cases based upon the Tyrer-Cuzick risk assessment. The study found that the Tyrer-Cuzick model was an accurate predictor of breast cancer risk among various ethnicities except for Hispanic women where it overestimated breast cancer risk (ratio of observed versus expected cases overall was 0.95).

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from more than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

Story continues

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read this article:
Myriad Presents New Data at ASCO Validating the Ability of riskScore to Provide Personalized Breast Cancer Risk Information to Patients - Yahoo...

3DHEALS 2020

SAN FRANCISCO (PRWEB) May 29, 2020

3DHEALS, LLC is pleased to announce its global virtual summit 3DHEALS 2020, June 5th- June 6th, focusing on healthcare innovations using 3D printing, bioprinting, and related technologies. The event expects 500+ attendees from 20+ countries, and 20 early-stage startups to participate in Pitch3D, a fast-paced pitch event to institutional investors. 3DHEALS 2020 addresses the need for a global cross-disciplinary forum. It will feature more than 70 world-class experts from more than 60 organizations and companies to showcase technological developments, share insights, tackle challenges, and present opportunities for future collaborations. The content-rich two-day multi-track virtual summit allows the attendees to learn practical knowledge from world-class experts, including hands-on application-focused workshops. The organizers have conducted more than 29 speaker interviews, which can also be downloaded as podcasts.

The virtual summit is not just two days of webinars, but a simulated virtual networking experience, where speakers, exhibitors, and attendees can engage through the conference's dedicated mobile app, before, during, and after the meeting. The fee for the conference is 100 USD.

The two-day virtual event offers nineteen sessions. While there is no dedicated COVID-19 panel, many presentations address how 3D printing and bioprinting communities respond to the pandemic.

Highlighted presentations and panels include the following:

In the first keynote presentation, Sam Onukuri, Head and Senior Fellow at Johnson & Johnson 3D Printing, will explain how the world's largest healthcare company is leveraging 3D printing technology to transform the design, manufacturing and delivery ecosystem across Johnson & Johnson's medical device, consumer and pharmaceutical businesses.

In the second keynote presentation, Dr. Alan Dang, an orthopedic spine surgeon and co-founder of PrinterPezz, will share the "behind-the-scenes secrets" of how PrinterPrezz democratizes medical device innovation and helps its customers go from concept to production.

The biofabrication and bioprinting panels collect some of the brightest minds in the world of tissue engineering and biofabrication, tackling 3D printing nearly every organ system from brain tissue, vasculatures, to heart valve. Many speakers are well-known scientists, including professors Stephanie Willerth, Adam Feinberg, Jordan Miller, who are also co-founders behind some of the newest startups in the bioprinting space. More established companies critical to tissue engineering and cell therapy will also join the conversation, including Melanie Mathieu from Prellis Biologics, Jon Rawley from Roosterbio, John O'Neil from Xylyx, Taciana Pereira from Allevi, and Kevin Caldwell from Ossium Health, and Qrquidea Garcia ("Orchid") from JNJ.

A related panel focusing on 3D printing on the International Space Station also deserves much attention from speakers from Techshot, ISS/CASIS, and Allevi (Ricky Solorzano).

The legal and regulatory panel will include the most comprehensive list of legal and regulatory concerns, focusing on healthcare 3D printing applications. The topics include intellectual property/patent issues(Roger Kuan, Haynes and Boone LLP), product liability, FDA pathways, manufacturing standards, and more. Steven Bauer, from FDA CBER, will address concerns related to cell therapy and stem cells.

The early morning Global Perspective sessions are reserved for international speakers to share their unique experiences, needs, and hopes. Both America Makes director John Wilczynski and NAMIC director Dr. Chaw Sing Ho, along with experts from Turkey, India, and Taiwan, will share how 3D printing and bioprinting innovations can thrive in both local and global healthcare environs. The audience will also learn about how different countries are implementing the concept of 3D printing for Point of Care, with experts from UCSF, Stanford, Germany (Kumovis), India (Anatomiz3D), Korea (MEDICALIP), and developing countries. More than ten 3DHEALS community managers will also present city-based healthcare 3D printing innovation ecosystems and share their progress.

As one of the largest sectors in FDA cleared devices, metal and orthopedic 3D printing will permeate throughout the entire conference, from keynotes to dedicated panels focusing on materials, designs (nTopology, ANSYS, MEDICALIP), and end-user applications head to toe (Printerprezz).

As a fast-growing sector, the dental 3D printing panel will feature an unprecedented group of speakers from a combination of academia (University of Michigan, USC, UOP) and industry (Boneeasy, Origin) focusing on critical issues facing the industry both short and long term.

The material science panel will feature speakers from Henkel, Evonik, Origin, and 3Degrees for an in-depth discussion on what roles material manufacturers should play in 3D printed medical devices, investment opportunities, and the latest trends.

The investor panel will feature VCs in the medtech and life science space, including NEA, Intuitive Surgical, Evonik, and more.

The entrepreneur fireside chat session will invite CEOs of Aspect Biosystems and Fluidform to share their perspectives based on their startup journeys.

Go here to see the original:
3DHEALS 2020: Join The Frontier Of Healthcare 3D Printing - PR Web

DUBLIN, May 28, 2020 /PRNewswire/ -- The "Nuclear Medicine Imaging Equipment - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis and the looming economic recession, the Nuclear Medicine Imaging Equipment market worldwide will grow by a projected US$525 Million, during the analysis period, driven by a revised CAGR of 2.9%. Hybrid Positron Emission Tomography (PET) Systems, one of the segments analyzed and sized in this study, is forecast to grow at over 3.5% and reach a market size of US$1.3 Billion by the end of the analysis period. The Hybrid Positron Emission Tomography (PET) Systems market will be reset to a new normal which going forwards in a post COVID-19 era will be continuously redefined and redesigned. Staying on top of trends and accurate analysis is paramount now more than ever to manage uncertainty, change and continuously adapt to new and evolving market conditions.

As part of the new emerging geographic scenario, the United States is forecast to readjust to a 1.8% CAGR. Within Europe, the region worst hit by the pandemic, Germany will add over US$12.2 Million to the region's size over the next 7 to 8 years. In addition, over US$13 Million worth of projected demand in the region will come from Rest of European markets. In Japan, the Hybrid Positron Emission Tomography (PET) Systems segment will reach a market size of US$62.5 Million by the close of the analysis period. Blamed for the pandemic, significant political and economic challenges confront China. Amid the growing push for decoupling and economic distancing, the changing relationship between China and the rest of the world will influence competition and opportunities in the Nuclear Medicine Imaging Equipment market. Against this backdrop and the changing geopolitical, business and consumer sentiments, the world's second largest economy will grow at 5.9% over the next couple of years and add approximately US$176.5 Million in terms of addressable market opportunity.

Continuous monitoring for emerging signs of a possible new world order post-COVID-19 crisis is a must for aspiring businesses and their astute leaders seeking to find success in the now changing Nuclear Medicine Imaging Equipment market landscape.

Competitors identified in this market include, among others:

Key Topics Covered:

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/e8egzt

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Visit link:
World Nuclear Medicine Imaging Equipment Market Analysis, Featuring Digirad Corporation, GE Healthcare, Mediso Medical Imaging Systems and Philips...

Precision Medicine Market2019 Industry Research Report provides important statistics, analytical and comparative data to give a complete understanding of the market Share, Size, Growth, Rising Trends and Cost Structure analysis.

Get Sample Copy of this Report at https://www.orianresearch.com/request-sample/559884

This report offers in-depth information obtained through extensive primary and secondary research methods. The information has been further assessed using various effective analytical tools.

The report puts special emphasis on the most important details of the Global Precision Medicine Market Report 2019 market, filtered out with the help of industry-best analytical methods

Regionally, North America, Latin America, Europe, Asia Pacific, And The Middle East & Africa constitute the key market segments.

Top Key Players Analyzed in Global Precision Medicine Marketare

Complete report on Precision Medicine Industry spread across 122 pages, profiling 10 companies and supported with tables and figures. For more details Enquire @https://www.orianresearch.com/enquiry-before-buying/559884

Key Benefit Of This Report:

Target Audience:

Get Direct Copy of this Report @https://www.orianresearch.com/checkout/559884

Major Points Covered in Table of Contents:

7 Global Precision Medicine Market By Product Type

8 Global Precision Medicine Market By Applications

9 Global Precision Medicine Market By Region

Customization Service of the Report:

Orian Research provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities

About UsOrian Researchis one of the most comprehensive collections of market intelligence reports on the World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

The rest is here:
COVID-19 Impact on Global Precision Medicine Industry 2020: Market Trends, Size, Applications, SWOT Analysis by Top Key Players and Forecast Report to...

The Global Genetic Testing Market is expected to register substantial growth in the near future due to rise in incidence of genetic disorders & cancer and growth in awareness and acceptance of personalized medicines.

Genetic testing is also known as DNA testing. Genetic testing is the study of gene present in cells and tissues. This study is further applied in the field of biology and medicine to better understand genetic disorders such as cancer, sickle cell anemia, cystic fibrosis, Down syndrome, and others. The scope of the report discusses the use of gene tests for the development of personalized medicine, targeted cancer treatment, and other genetic diseases.

In addition, advancements in genetic testing techniques and increasing application of genetic testing in oncology are expected to boost the market growth during the forecast period.Genetic tests involve a set of lab tests for the study of the genetic makeup of patients and identify any gene mutations and alterations in the healthy structure of DNA leading to the development of genetic disorders. The Geographical Segmentation includes study of global regions such as North America, Latin America, Asia-Pacific, Africa, and Europe. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.

Get Sample Copy of this [emailprotected] https://www.marketresearchinc.com/request-sample.php?id=16612

Highlighted key points of this market research report:

Profiling Key Players:

Get Maximum Discount Now @ https://www.marketresearchinc.com/ask-for-discount.php?id=16612

Genetic Testing Key Market Segments:

By Product Type:

By Technology Type:

By Application Type:

Different top-level key players are also enlisted in order to obtain in-depth knowledge and informative data of companies. Some of the key players are also profiled in this research report, which includes Genetic Testing Market. Different industry analysis tools such as SWOT and Porters five-technique are further used while analyzing the global Genetic Testing Market.

For More Inquiry Detailed TOC Of Research Report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=16612

The report also draws attention to recent advancements in technologies and certain methodologies which further help to boost the outcome of the businesses. Furthermore, it also offers a comprehensive data of cost structure such as the cost of manpower, tools, technologies, and cost of raw material. The report is an expansive source of analytical information of different business verticals such as type, size, applications, and end-users.

Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market.

Table of Content:

Chapter 1:Genetic Testing Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Genetic Testing Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Genetic Testing Market Effect Factors Analysis

Chapter 12: GlobalGenetic Testing Market Forecast to 2025

Finally, all aspects of the Genetic Testing Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects.

About Us:Market Research Inc is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

Contact Us:Author KevinUS Address: 51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225 1818Email: [emailprotected]

Read the original:
Rapid Growth on Genetic Testing Market with COVID-19 Impact Analysis, Top Key Companies like Abbott Laboratories Bio-Rad Laboratories Inc.,...

The global Regenerative Medicine market study presents an all in all compilation of the historical, current and future outlook of the market as well as the factors responsible for such a growth. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities and threats of each Regenerative Medicine market player in a comprehensive way. Further, the Regenerative Medicine market report emphasizes the adoption pattern of the Regenerative Medicine across various industries.

The Regenerative Medicine market report examines the operating pattern of each player new product launches, partnerships, and acquisitions has been examined in detail.

The report on the Regenerative Medicine market provides a birds eye view of the current proceeding within the Regenerative Medicine market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the Regenerative Medicine market and offers a clear assessment of the projected market fluctuations during the forecast period.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.researchmoz.com/enquiry.php?type=S&repid=2656563&source=atm

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Regenerative Medicine market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Regenerative Medicine market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Regenerative Medicine market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Regenerative Medicine market.The following players are covered in this report:DePuy SynthesMedtronicZimmerBiometStrykerAcelityMiMedx GroupOrganogenesisUniQureCellular Dynamics InternationalOsiris TherapeuticsVcanbioGamida CellGolden MeditechCytoriCelgeneVericel CorporationGuanhao BiotechMesoblastStemcell TechnologiesBellicum PharmaceuticalsRegenerative Medicine Breakdown Data by TypeCell TherapyTissue EngineeringBiomaterialOtherRegenerative Medicine Breakdown Data by ApplicationDermatologyCardiovascularCNSOrthopedicOthers

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2656563&source=atm

The Regenerative Medicine market report offers a plethora of insights which include:

The Regenerative Medicine market report answers important questions which include:

The Regenerative Medicine market report considers the following years to predict the market growth:

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2656563&licType=S&source=atm

Why Choose Regenerative Medicine Market Report?

Regenerative Medicine Market Reportfollows a multi- disciplinary approach to extract information about various industries. Our analysts perform thorough primary and secondary research to gather data associated with the market. With modern industrial and digitalization tools, we provide avant-garde business ideas to our clients. We address clients living in across parts of the world with our 24/7 service availability.

See the article here:
Coronavirus threat to global Regenerative Medicine Market boosting the growth Worldwide: Market dynamics and trends, efficiencies Forecast 2023 - News...

A local hospital is using a little-known medicine to treat COVID-19 patients after the FDA authorized compassionate use approval to administer the drug.

Landmark Hospital of Athens treated two patients with its first doses of the medicine last week, according to a press release from Landmark Hospitals, which operates six long-term acute-care hospitals in the Southeast, including its Athens hospital on Sunset Drive.

The medicine, called Organicell Flow, is a biologic product derived from amniotic fluid, which contains stem cells. Amniotic fluid is the protective fluid in the sac containing growing fetuses.

Landmark is providing the product to patients with advanced COVID-19 conditions, according to the company.

After receiving Organicell Flow intravenously last week, the two patients were clinically stable as of Wednesday, according to Landmark.

Organicell Regenerative Medicine of Boca Raton, Fla., manufactures the medicine from human amniotic fluid voluntarily donated during Cesarean section surgeries, according to Landmark.

Developed to promote wound healing, Organicell Flow contains more than 300 growth factors, cytokines and chemokines, as well as hyaluronic acid and exosomes, according to the press release.

The medicine can modulate a patients immune response. In some COVID-19 patients, their supercharged immune response can be as harmful as the actual coronavirus that causes COVID-19.

The condition, called cytokine storm syndrome, can damage lungs and other organs and can lead to death, said Landmark Hospitals Chairman Dr. William Kapp.

The data collected from the patients receiving compassionate use treatments will guide us to interventions that modulate COVID-19 immune response in the lungs and reduce systemic organ damage, Kapp said in Landmarks press release.

Organicell Flow is one of a number of medicines health providers around the world are trying out to treat COVID-19, which has claimed more than 100,000 lives in the United States so far and nearly 2,000 in Georgia.

Two other Athens hospitals have also recently received shipments of another drug that may help patients with COVID-19, remdesivir.

Gov. Brian Kemp announced earlier this week that the state was distributing more than 18,000 vials of remdesivir to more than 80 Georgia hospitals, enough to treat nearly 17,000 patients. The hospitals include Athens St. Marys Healthcare System and the Piedmont system that includes Piedmont Athens Regional and several other Georgia hospitals.

Remdesivir is being used to treat patients with serious symptoms such as low oxygen levels or pneumonia, according to the Georgia Department of Public Health.

Developed to treat people with Ebola virus disease, remdesivir has been shown to shorten the time of recovery from COVID-19 illness in hospitalized patients, but in the absence of thorough studies is considered investigational.

Standard treatment for COVID-19 includes oxygen therapy, mechanical ventilation and medicine to maintain blood pressure.

Read the original post:
Athens hospital using biologic treatment on COVID-19 patients - Online Athens

A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.

Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.

Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.

Related: The 9 most interesting transplants

Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.

But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.

The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.

In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.

It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.

The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.

In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.

These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.

Related: First pig-monkey chimeras were just created in China

But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.

This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."

These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.

The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.

Feng said that much discussion needs to take place before such applications can be considered.

"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.

"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.

The findings were published in the journal Science Advances on May 13.

Originally published on Live Science.

See original here:
New human-mouse chimera is the most human yet - Livescience.com